Table 1.
Institutions | Date | Technology | Clinical Trials | Details | Ref |
---|---|---|---|---|---|
University of Pennsylvania/Novartisa | August, 2012 | CTL019 | NCT02167360, NCT02228096, NCT02030834, NCT01626495, NCT01029366 | CD19-specific CAR for B Cell Acute Lymphoblastic Leukemia (B-ALL) | [32] |
Juno Therapeuticsb,c | December, 2013 | JCAR015 | NCT01044069, NCT01840566 | CD19-specific CAR for B-ALL and non-Hodgkin lymphoma (NHL) | [30, 109–111] |
JCAR017 | NCT02028455 | CD19-specific CAR for leukemia | |||
JCAR014 | NCT01865617 | CD19-specific CAR for chronic lymphocytic leukemia, NHL, ALL | |||
JTCR016 | NCT01640301, NCT00052520 | WT1-specific TCR for leukemia, myelodysplastic syndrome | |||
Exploration of other targetsd |
Preclinical |
L1CAM: neuroblastoma, glioblastoma, lung cancer, pancreatic cancer, and ovarian cancer MUC-16: ovarian cancer ROR-1: lung cancer, triple negative breast cancer, pancreatic cancer, prostate cancer, ALL |
|||
Juno/Opus Bio, Inc./National Cancer Institute (NCI)e | December, 2014 | CD22-CAR | NCT02315612, NCT02159495 | Leukemia, lymphoma | |
Celgene/Bluebird Bio/Baylorf | March, 2013 | Hematological/Solid Tumors | |||
Kite Pharmaceuticals/National Cancer Instituteg,h | October, 2012 | CD19-CAR | NCT00924326, NCT02348216 | B-cell leukemia, lymphoma | [112, 113] |
EGFRvlll-CAR | NCT01454596 | Glioblastoma | [114, 115] | ||
NY-ESO-1 TCR | NCT01967823 | ESO-expressing tumors | |||
HPV-16E6 TCR | NCT0228081 | Cervical/Head & Neck Cancer | |||
HPV-16E7 TCR | Cervical/Head & Neck Cancer | ||||
MAGE A3 TCR | NCT02111850 | MAGE-A3-DP4-expressing tumors | |||
SSX2 TCR | NCT02153905 | MAGE-A3-expressing tumors, metastatic melanoma | |||
Kite Pharmaceuticals/Amgen | January, 2015 | Exploration of other targets | Preclinical | Hematologic cancers and solid tumors | |
MD Anderson/Ziopharm Oncology/lntrexonj | January, 2015 | RheoSwitch Therapeutic System | Preclinical | Switches for control of dynamic range, spatial expression, and temporal expression | |
Non-Viral Integration | Sleeping Beauty transposon system for integration of CARs in T cells | ||||
Universal donor | Preclinical | ||||
CD19-specific CAR | NCT01497184, NCT01653717 | Leukemia, lymphoma | |||
Cellectis/Ohio State Universityk | January, 2015 | CS1-specific CAR | Preclinical | Multiple myeloma | |
Pfizer/Cellectisl | June, 2014 | Working on several targets for CAR therapy | |||
GlaxoSmithKline/Adaptimmunem | June, 2014 | NY-ESO-1 TCR | NCT01350401, NCT01567891, NCT01892293 | Multiple myeloma, melanoma, sarcoma, and ovarian cancer | |
Advanced Designs for Adoptive T Cell Therapy | |||||
Servier/Cellectisn | February, 2014 | UCART19 | Filing for clinical trial authorization | Off-the shelf T cell for leukemia | |
Unum Therapeuticso | 2014 | ACTR+anti-CD20 antibody | NCT02315118 | Leukemia, Non-Hodgkin’s lymphoma | [51] |
Bellicum Pharmaceuticals | 2011 | GoCAR-T | Preclinical | Prostate stem cell antigen-expressing solid tumors | [50] |
Bellicum Pharmaceuticals/Texas Children’s Hospital/Baylor College of Medicine | 2011 | CaspaCIDe | NCT01494103 | Graft-versus-host disease | [67] |
Bluebird bio (Acquisition of Pregenen)p | June, 2014 | Homing endonucleases, MegaTALEs | |||
Novartis/lntelliaq | January, 2015 | CRISPR |